Journal
JOURNAL OF NATURAL PRODUCTS
Volume 81, Issue 3, Pages 534-542Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jnatprod.7b00912
Keywords
-
Funding
- NIH [2P01 CA125066, GM08512, 5T32 AT007533]
- NATIONAL CANCER INSTITUTE [P01CA125066] Funding Source: NIH RePORTER
- National Center for Complementary & Integrative Health [T32AT007533] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008512] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The human 20S proteasome inhibitor scytonemide A (1), a macrocyclic imine originally isolated from the cyanobacterium Scytonema hofmanni, was synthesized via a biomimetic solid-phase peptide synthesis (SPPS) approach employing the Weinreb AM resin. Utilizing this approach, cyclization of the protected heptapeptide via formation of the imine bond occurred spontaneously upon cleavage from the resin in the presence of a reducing agent and subsequent aqueous workup. The final deprotection step necessary to produce the natural product was accomplished under slightly basic conditions, facilitating cleavage of the silyl ether group while leaving the macrocycle intact. Purification of the synthetic scytonemide A was accomplished via normal-phase flash column chromatography, potentially facilitating larger scale preparation of the compound necessary for future mechanistic and SAR studies. The structure of the target compound was confirmed by NMR spectroscopy, which also shed light on differences in the spectroscopic data obtained for the synthetic and natural scytonemide A samples for some of the amide and alcohol signals in the H-1 NMR spectrum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available